Skip to main content
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Renal-Cell Carcinoma
Minimal Activity with Sapanisertib in Refractory Renal-Cell Carcinoma
Read More
Renal-Cell Carcinoma
Active Therapy Improves Survival versus BSC After Disease Progression on Nivolumab and Cabozantinib
Read More
Renal-Cell Carcinoma
Real-World Treatment Patterns Have Drastically Changed Over the Past 5 Years
Read More
Renal-Cell Carcinoma
Functional Imaging Predicts Outcomes in Patients Treated with Antiangiogenic Therapy
Read More
Renal-Cell Carcinoma
Development of a Prognostic Biomarker Score for Nivolumab in Relapsed/Refractory Disease
Read More
Renal-Cell Carcinoma
Clinical Activity of Lenvatinib with or without Everolimus in Heavily Pretreated Disease
Read More
Renal-Cell Carcinoma
Nivolumab Rechallenge Associated with Moderate Efficacy
Read More
Renal-Cell Carcinoma
Stereotactic Radiotherapy Delays Treatment Switch in Those with Oligoprogression
Read More
Renal-Cell Carcinoma
Study 218: Higher Lenvatinib Starting Dose Trended Toward Better Outcomes
Read More
Renal-Cell Carcinoma
BREAKPOINT: Cabozantinib Efficacious After Treatment with First-Line Immunotherapy
Read More
1
2
Page 1 of 2
Results 1 - 10 of 19
